AVP and breast cancer: At present, a ‘one size fits all’ approach to follow-up is used for women diagnosed with ADH and LN, as BC risk prediction models have shown poor discrimination for women with atypia [15, 18], with several models either significantly over- or underestimating their risk of subsequent breast cancer [16, 17, 34].